University of Michigan Rogel Cancer Center: Prostatic Neoplasms trials

The registry lists 35 Prostatic Neoplasms studies with University of Michigan Rogel Cancer Center as lead sponsor. 8 are open to participants now and 14 have results posted.

Phase 1 8Phase 2 18No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07682649Phase 1
• Targeted Early Detection Program in Men at High Genetic Risk for Prostate CancerRecruitingNCT07645391
• Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE TrialRecruitingNCT07526545Not applicable
• A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer PatientsRecruitingNCT07291414Not applicable
• SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) TherapyRecruitingNCT07096999
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
• Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic ProbeRecruitingNCT05965180
• Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])RecruitingNCT05038332Phase 2
• Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot StudyCompletedNCT05764005Not applicableResults posted
• Michigan Genetic Hereditary Testing (MiGHT)CompletedNCT05162846Not applicableResults posted
• Lighting Intervention for Cancer-related FatigueCompletedNCT04827446Not applicableResults posted
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results posted
• Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate CancerTerminatedNCT03689582Phase 2Results posted
• FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)CompletedNCT03556904Phase 2Results posted
• ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate CancerTerminatedNCT03300505Phase 1Results posted
• Vessel Sparing Prostate Radiation TherapyCompletedNCT02958787Phase 2Results posted
• Genomics in Michigan Impacting Observation or RadiationCompletedNCT02783950Not applicableResults posted
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerCompletedNCT02059213Phase 2Results posted
• Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate CancerTerminatedNCT01642732Phase 1Results posted
• Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to BoneTerminatedNCT01428219Phase 2Results posted
• Hypofractionated Stereotactic Body Radiation Therapy (SBRT)CompletedNCT01288534Phase 2Results posted
• Salvage Radiation Therapy and Taxotere for PSA Failure After Radical ProstatectomyTerminatedNCT00480857Phase 2Results posted
• Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)Active, not recruitingNCT04748042Phase 2
• Testing the Effect of Mindfulness for Prostatectomy OutcomesTerminatedNCT04727710Not applicable
• Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerCompletedNCT04703920Phase 1
• Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate CancerActive, not recruitingNCT04396808Not applicable
• Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerWithdrawnNCT04272645Phase 2
• A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerActive, not recruitingNCT04194554Phase 1/2
• Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate CancerCompletedNCT02946008Phase 1
• Early Assessment of Treatment Response Using Functional Diffusion MappingCompletedNCT02064283Not applicable
• Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate CancerCompletedNCT00151086Phase 1/2
• Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateCompletedNCT00151073Phase 2
• Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate CancerCompletedNCT00151047Phase 2
• Tetrathiomolybdate in Hormone Refractory Prostate CancerCompletedNCT00150995Phase 2
• Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate CancerCompletedNCT00134355Phase 2